Related Experiment Video
Updated: Aug 8, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.3K
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Gianfranco Di Giuseppe1, Gea Ciccarelli1, Laura Soldovieri1
1Endocrinologia e Diabetologia, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Trends in Endocrinology and Metabolism: TEM
|March 1, 2023
Summary
Impaired first-phase insulin secretion is key in type 2 diabetes mellitus (T2DM) progression, impacting glucose control and beta cell health. Understanding this defect aids in managing hyperglycemia and developing new therapeutic strategies.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Diabetes Research
Background:
- Type 2 Diabetes Mellitus (T2DM) is a complex metabolic disorder characterized by hyperglycemia.
- Beta-cell dysfunction, specifically impaired insulin secretion, plays a critical role in T2DM pathogenesis.
- The significance of first-phase insulin secretion in the natural history and management of T2DM requires further elucidation.
Purpose of the Study:
- To investigate the role of first-phase insulin secretion in T2DM.
- To explore the relationship between impaired secretion, insulin resistance, and beta-cell function/mass.
- To review therapeutic strategies for early secretory defects and beta-cell restoration.
Main Methods:
- Review of human and animal data.
- Pathophysiological analysis of glucose homeostasis.
- Exploration of clinical and preclinical evidence.
Main Results:
- Impaired first-phase insulin secretion significantly impacts glucose homeostasis and contributes to postmeal hyperglycemia in T2DM.
- This defect is closely linked to insulin resistance and alterations in beta-cell function and mass.
- Dietary and pharmacological interventions show potential for improving early secretory defects.
Conclusions:
- First-phase insulin secretion is a crucial factor in T2DM development and progression.
- Understanding and targeting early secretory defects offers a promising avenue for T2DM management.
- Further research into detecting and treating these defects is warranted for improved patient outcomes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
223
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
223
01:27Insulin Formulations: Types and Delivery
245
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
245
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
01:24Glucagon-like Receptor Agonists
380
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
380
01:15Diabetes: Management and Pharmacotherapy
323
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
323
01:25Insulin: Biosynthesis, Chemistry, and Preparation
455
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
455